Copyright
©20???? Baishideng Publishing Group Co., Limited. All rights reserved.
World J Clin Oncol. Oct 10, 2012; 3(10): 137-141
Published online Oct 10, 2012. doi: 10.5306/wjco.v3.i10.137
Published online Oct 10, 2012. doi: 10.5306/wjco.v3.i10.137
Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin
Tal Grenader, Ora Rosengarten, Rut Isacson, Yevgeni Plotkin, Alberto Gabizon, Department of Oncology, Sha’are Zedek Medical Center, Jerusalem 91031, Israel
Author contributions: Grenader T and Gabizon A contributed to the conception and design; Grenader T, Gabizon A, Rosengarten O and Isacson R contributed to acquisition of data; Grenader T, Rosengarten O and Gabizon A contributed to analysis and interpretation of data; Grenader T, Rosengarten O, Isacson R, Gabizon A and Plotkin Y contributed to drafting and revising the article; Grenader T, Rosengarten O, Isacson R, Gabizon A and Plotkin Y approved the final version of publication.
Correspondence to: Tal Grenader, MD, Department of Oncology, Sha’are Zedek Medical Center, PO Box 3235, Jerusalem 91031, Israel. talgrenader65@hotmail.com
Telephone: +972-2-6666378 Fax: +972-2-6666731
Received: June 26, 2012
Revised: September 14, 2012
Accepted: September 28, 2012
Published online: October 10, 2012
Revised: September 14, 2012
Accepted: September 28, 2012
Published online: October 10, 2012
Core Tip